Novelta Chewable Tablet : Each chewable tablet contains Magaldrate USP 480 mg and Simethicone USP 20 mg.
Novelta 100 ml Suspension : Each 5 ml suspension contains Magaldrate USP 480 mg and Simethicone USP 20 mg.
Novelta 200 ml Suspension : Each 5 ml suspension contains Magaldrate USP 480 mg and Simethicone USP 20 mg.

USP

Antiulcerant

Novelta is indicated in hyperacidity, gastric and duodenal ulcer, gastritis, heartburn, dyspepsia, gastroesophageal reflux. Novelta is also indicated for the relief of flatulence, abdominal distention and windy colic.

Magaldrate is contraindicated in patient with known hypersensitivity to magnesium and aluminium. It is also contraindicated in patient with impaired renal function.

Novelta Chewable Tablet: 1-4 tablets, 20 minutes to 1 hour after meals and at bedtime, or as directed by the physician. Novelta Suspension: 2-4 teaspoonful (10 to 20 ml), 20 minutes to 1 hour after meals and at bedtime, or as directed by the physician.

Mild constipation may occur in a small percentage of patients.

Patient should be cautious, if allergic to any ingredients of Novelta, with a history of kidney problems or taking citrate salts (found in some calcium supplements, antacids, and laxatives). Do not take with tetracycline antibiotics. Antacids can interfere with the absorption of iron preparations. Children: Not recommended under 6 years of age unless properly diagnosed. Lactation: No known risk as the  drug does not appear to be absorbed by GIT. Pregnancy: Pregnancy Category-C, use only when necessary, avoid chronic high dose.

It should not be used in patients who are taking Tetracycline. The drug may cause reduced bio-availability or slower absorption of a no of drugs including propranolol, isoniazid prednisolone and Naproxen

Novelta Chewable Tablet: Each blister box contains 10x10\\\\\\\\\\\\\\\'s tablet.
Novelta  100 ml Suspension: Each amber glass bottle contains 100 ml suspension.
Novelta  200 ml Suspension: Each PET bottle contains 200 ml suspension.